/ /

dry eye

New products, advancements in dry eyeDavid Kading, OD, FAAO, FCLSA, discusses new products, studies, and patient education available to help combat dry eye disease.
Understanding the link between MGD and OSDMeibomian gland dysfunction (MGD) may be misdiagnosed. While MGD is one of the most common chronic ocular conditions, diagnosing MGD isn’t as simple as it seems.
How to use tear osmolarity to help treat dry eye diseaseFor the patient, perhaps the most significant symptom of DED is fluctuating or reduced vision.
Cataract surgery for patients with PXFMom has pseudoexfoliation syndrome (PXF) clinically visible in both eyes. She experiences pops of elevated intraocular pressure (IOP) in one eye and uses glaucoma medications.
The utility of normal tear osmolarity results
The utility of normal tear osmolarity resultsPatient symptoms are not an effective method to diagnose dry eye, as they often overlap with other pathologies. Tear osmolarity results provide clues for alternative diagnoses.
Lifitegrast data support dry eye efficacy over placebo dropsLifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
Protein agent may change approach to treating dry eye, inflammationRecombinant human lubricin showed potential as a new therapeutic approach to the management of dry eye disease in a small clinical trial. Compared with sodium hyaluronate, lubricin (Lubris BioPharma), significantly improved both signs and symptoms of moderate dry eye after two weeks of treatment.
Exploring off-label, investigational approaches for allergic conjunctivitisSeasonal and perennial allergic conjunctivitis are common conditions that are not always well-controlled with conventional therapy. Alternative approaches and novel investigational treatments are discussed.
Novel topical peptide for dry eye tackles underlying cause of diseaseA phase I/II trial enrolling patients with Sjögrens syndrome dry eye will be investigating  a synthetic fragment of a naturally occurring tear glycoprotein. Findings from extensive laboratory and preclinical research suggest that it is a promising novel therapy.
Novel neurostimulator device uses nasal cavities to stimulate tearsChronic dry eye disease (DED) affects more than 25 million people and to date the only pharmacologic therapies are topical or involve punctal plugs. Results from two studies wth a neurostimulator indicate there may be a new pathway to upregulate the body’s tear system.